Related references
Note: Only part of the references are listed.Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2008)
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue
Raghavan Chinnadurai et al.
JOURNAL OF VIROLOGY (2007)
AIDS virus envelope spike structure
Kenneth H. Roux et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2007)
Biophysical evidence of two docking sites of the carboxyl heptad repeat region within the amino heptad repeat region of gp41 of human immunodeficiency virus type 1
Ding-Kwo Chang et al.
ANTIVIRAL RESEARCH (2007)
HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides
Shuwen Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds
Shuwen Liu et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
SW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
SB Jiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors
SW Liu et al.
PEPTIDES (2003)
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
M Armand-Ugón et al.
ANTIVIRAL RESEARCH (2003)
Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state
KE Follis et al.
JOURNAL OF VIROLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex
J Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis
M Lu et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
